Tenofovir Disoproxil Fumarate
Tenofovir Disoproxil Fumarate 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Healthy Volunteer、Weight Gain、Metabolic Effects、Integrase Strand Transfer Inhibitors。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
8 项
已进入 III/IV 期
13 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- National Institute of Allergy and Infectious Diseases (NIAID)
- University of Florida
- University of Witwatersrand, South Africa
- The First Affiliated Hospital of Zhengzhou University
- Oswaldo Cruz Foundation
- Icahn School of Medicine at Mount Sinai
- José Antonio Mata Marín
- Third Affiliated Hospital, Sun Yat-Sen University
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、South Africa、中国、Brazil、Mexico、Malawi、Colombia、Dominican Republic、Guatemala、Russia、Thailand、法国
正在招募患者的 Tenofovir Disoproxil Fumarate 研究
ANCHORS Alcohol & Sexual Health Study: UH3 Project
IV 期招募中美国NCT04331704Post-Injectable Cabotegravir Antiretroviral Salvage Strategy Options Trial
IV 期招募中South AfricaNCT06485154Observation Study on Reducing the Risk of Liver Cancer Associated With Hepatitis B (Zhiyuan) Project.
不适用招募中中国NCT07169656Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study
II 期招募中美国NCT05652478ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention
不适用招募中BrazilNCT07497594Antiviral Clinical Trial for Long Covid-19
II 期招募中美国NCT06511063DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity
III 期招募中MexicoNCT07075146Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients
IV 期招募中中国NCT05182463Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease
I 期招募中中国NCT06356662Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF
不适用招募中中国NCT03920618UNCPM 22314 - Pregnancy, Infant and Maternal Health Outcomes Study
IV 期招募中MalawiNCT06158126Improving Access to PrEP (HIV Prevention Medication) for People in Underserved Areas of Rio de Janeiro
不适用招募中BrazilNCT07584122Comparison of TAF and TDF in Preventing Mother-to-Child Transmission of HBV in Pregnancies With High Viral Loads
不适用招募中中国NCT06947356ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection
IV 期招募中中国NCT07573943Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)
II 期招募中美国ColombiaDominican RepublicGuatemalaNCT04375800DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road)
II 期招募中法国NCT06034938Pegylated Interferon α in Previously Interferon-treated CHB（Leading Study）
不适用招募中中国NCT06323681PrEPsmart 2-1-1 Pilot
II 期招募中美国NCT06631365Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.
不适用招募中中国NCT04231565TAF (Tenofovir Alafenamide) for Preventing Progression of Liver Disease in Non-cirrhotic Chronic HBV Infection With Normal ALT and Low Viral Load.
不适用招募中IndiaNCT05195450Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France.
III 期招募中法国ThailandNCT05813964Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment
III 期招募中BrazilNCT06497465Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
不适用招募中美国NCT07473778Clinical Outcomes of HBeAg-negative CHB Patients With Indeterminate Phase
不适用招募中中国NCT05661786
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。